Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

Bertocchio JP, Warnock DG, Jaisser F.

Kidney Int. 2011 May;79(10):1051-60. doi: 10.1038/ki.2011.48. Epub 2011 Mar 16. Review.

PMID:
21412221
[PubMed - indexed for MEDLINE]
2.

[Aldosterone and kidney diseases: an emergent paradigm with important clinical implications].

Bertocchio JP, Jaisser F.

Nephrol Ther. 2011 Jun;7(3):139-47. doi: 10.1016/j.nephro.2010.10.012. Epub 2010 Dec 8. Review. French.

PMID:
21144811
[PubMed - indexed for MEDLINE]
3.

Mineralocorticoid receptor activation in obesity hypertension.

Nagase M, Fujita T.

Hypertens Res. 2009 Aug;32(8):649-57. doi: 10.1038/hr.2009.86. Epub 2009 Jun 12. Review.

PMID:
19521418
[PubMed - indexed for MEDLINE]
4.

Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers.

Nishiyama A, Hitomi H, Rahman A, Kiyomoto H.

J Pharmacol Sci. 2009 Jan;109(1):1-6. Review.

PMID:
19151533
[PubMed - indexed for MEDLINE]
Free Article
5.

Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Nagase M.

Clin Exp Nephrol. 2010 Aug;14(4):303-14. doi: 10.1007/s10157-010-0298-8. Epub 2010 Jun 9. Review.

PMID:
20533072
[PubMed - indexed for MEDLINE]
6.

Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.

Waanders F, de Vries LV, van Goor H, Hillebrands JL, Laverman GD, Bakker SJ, Navis G.

Curr Vasc Pharmacol. 2011 Sep;9(5):594-605. Review.

PMID:
21529330
[PubMed - indexed for MEDLINE]
7.

Aldosterone in the pathogenesis of chronic kidney disease and proteinuria.

Lu Y, Ku E, Campese VM.

Curr Hypertens Rep. 2010 Aug;12(4):303-6. doi: 10.1007/s11906-010-0116-4. Review.

PMID:
20596805
[PubMed - indexed for MEDLINE]
9.

Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.

Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.

Eur J Pharmacol. 2008 Jul 28;589(1-3):264-71. doi: 10.1016/j.ejphar.2008.06.019. Epub 2008 Jun 10.

PMID:
18582458
[PubMed - indexed for MEDLINE]
10.

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.

Sato A, Hayashi K, Saruta T.

Am J Hypertens. 2005 Jan;18(1):44-9.

PMID:
15691616
[PubMed - indexed for MEDLINE]
11.

Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome.

Shibata S, Fujita T.

Mol Cell Endocrinol. 2012 Mar 24;350(2):273-80. doi: 10.1016/j.mce.2011.07.018. Epub 2011 Jul 27. Review.

PMID:
21820485
[PubMed - indexed for MEDLINE]
12.

Aldosterone, mineralocorticoid receptor, and heart failure.

Messaoudi S, Azibani F, Delcayre C, Jaisser F.

Mol Cell Endocrinol. 2012 Mar 24;350(2):266-72. doi: 10.1016/j.mce.2011.06.038. Epub 2011 Jul 18. Review.

PMID:
21784127
[PubMed - indexed for MEDLINE]
13.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
[PubMed - indexed for MEDLINE]
14.

Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/mineralocorticoid receptor system.

Nagase M, Fujita T.

Curr Diabetes Rev. 2011 Jan;7(1):8-16. Review.

PMID:
21067506
[PubMed - indexed for MEDLINE]
15.

Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?

Lattanzio MR, Weir MR.

Curr Hypertens Rep. 2010 Oct;12(5):369-77. doi: 10.1007/s11906-010-0142-2. Review.

PMID:
20703958
[PubMed - indexed for MEDLINE]
16.

Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.

Rafiq K, Hitomi H, Nakano D, Nishiyama A.

J Pharmacol Sci. 2011;115(1):1-7. Epub 2010 Dec 21. Review.

PMID:
21186336
[PubMed - indexed for MEDLINE]
Free Article
17.

Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.

Ku E, Campese VM.

Pediatr Nephrol. 2009 Dec;24(12):2301-7. doi: 10.1007/s00467-009-1176-z. Epub 2009 Apr 4. Review.

PMID:
19347366
[PubMed - indexed for MEDLINE]
18.

[Mineralocorticoid receptor].

Nishiyama A, Kiyomoto H, Kohno M.

Nihon Rinsho. 2009 Apr;67(4):695-700. Review. Japanese.

PMID:
19348230
[PubMed - indexed for MEDLINE]
19.

[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].

Nagase M, Fujita T.

Nihon Jinzo Gakkai Shi. 2010;52(2):125-31. Review. Japanese. No abstract available.

PMID:
20415233
[PubMed - indexed for MEDLINE]
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk